Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Shang-Ying Liang"'
Publikováno v:
Future oncology (London, England). 17(32)
Aim: To investigate real-world overall survival (rwOS) and real-world progression-free survival (rwPFS) in locally advanced/metastatic urothelial carcinoma postplatinum and postprogrammed death receptor-1/death ligand 1 inhibitors. Patients & methods
Autor:
Peter H. O'Donnell, Noah M. Hahn, Elaina M. Gartner, Matthew D. Galsky, Shang Ying Liang, Daniel P. Petrylak, Amal Melhem-Bertrandt, Evan Y. Yu, Juan Pinelli, Arjun Vasant Balar, Elisabeth I. Heath, Bradley Alexander McGregor, Jonathan E. Rosenberg
Publikováno v:
Journal of Clinical Oncology. 37:2592-2600
PURPOSE Locally advanced or metastatic urothelial carcinoma is an incurable disease with limited treatment options, especially for patients who were previously treated with platinum and anti–programmed death 1 or anti–programmed death ligand 1 (P
Autor:
Janet Trowbridge, Peter H. O'Donnell, Arjun Vasant Balar, Joyce Steinberg, Evan Y. Yu, Jae-Lyun Lee, Mark N. Stein, Andrea Necchi, Michael R. Harrison, Daniel P. Petrylak, Shang-Ying Liang, Bradley Alexander McGregor, Se Hoon Park, David I. Quinn, Michiel S. van der Heijden, Mary Campbell, Yohann Loriot, Takahiro Kojima, Jonathan E. Rosenberg, Elisabeth I. Heath
Summary Background Locally advanced or metastatic urothelial carcinoma is generally incurable and has scarce treatment options, especially for cisplatin-ineligible patients previously treated with PD-1 or PD-L1 therapy. Enfortumab vedotin is an antib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4439042fdb691a716c5dade5f1b9990
Autor:
Elisabeth I. Heath, Andrea Necchi, Takahiro Kojima, Mark N. Stein, Michiel S. van der Heijden, Janet Trowbridge, Daniel P. Petrylak, Joyce Steinberg, Se Hoon Park, Evan Y. Yu, Yohann Loriot, Bradley Alexander McGregor, Michael R. Harrison, Arjun Vasant Balar, Shang-Ying Liang, Jonathan E. Rosenberg, Jae-Lyun Lee
Publikováno v:
Journal of Clinical Oncology. 39:4524-4524
4524 Background: Cisplatin (cis)-ineligible, platinum-naive patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) who progress on/after anti-PD-1/L1 treatment (tx) have a poor prognosis and few tx options. Enfortumab vedoti
Autor:
Michiel S. van der Heijden, Joyce Steinberg, Janet Trowbridge, Evan Y. Yu, Yohann Loriot, Elisabeth I. Heath, Jonathan E. Rosenberg, Mark N. Stein, Eric H. Kim, Se Hoon Park, Andrea Necchi, Shang-Ying Liang, Michael R. Harrison, Mary S. Campbell, Arjun Vasant Balar, Daniel P. Petrylak, Bradley Alexander McGregor, Jae-Lyun Lee
Publikováno v:
Journal of Clinical Oncology. 39:394-394
394 Background: Cisplatin (cis)-ineligible, platinum-naive patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) who progress on/after PD-1/L1 inhibitors (PD-1/L1-i) have a poor prognosis and few treatment (tx) options. Enf
Autor:
Reshma A. Rangwala, Hye Sook Chon, Shweta Jain, Shang-Ying Liang, Leonardo Viana Nicacio, Donna M. McNamara, Haider Mahdi, David M. O'Malley, Steven Robert Schuster
Publikováno v:
Journal of Clinical Oncology. 37:TPS5602-TPS5602
TPS5602 Background: Ovarian cancer (OC) is the most lethal gynecologic cancer, accounting for ≈185,000 deaths worldwide in 2018. Most patients (pts) initially respond to platinum-based chemotherapy (chemo), but more than 50% of pts recur. Pts who r
Autor:
Megan M. O'Meara, Farhad Ravandi, Lionel Ades, Amir T. Fathi, Karl Anton Kreuzer, Eunice S. Wang, Shang-Ying Liang
Publikováno v:
Journal of Clinical Oncology. 35:TPS7066-TPS7066
TPS7066 Background: AML is associated with poor survival rates in patients (pts) who are not eligible for intensive chemotherapy or allogeneic stem cell transplant (allo-SCT) due to advanced age, comorbidities, and/or disease risk factors. Non-intens
Autor:
Dot Chin, S. S. Bacus, Aysegul A. Sahin, Francisco J. Esteva, Shang Ying Liang, Gabriel N. Hortobagyi, Terry L. Smith, Aman U. Buzdar, Lajos Pusztai
Publikováno v:
Pathology & Oncology Research. 7:171-177
The purpose of this study was to investigate the frequency of expression of the erbB/HER family of growth factor receptors, their ligand heregulin, and the two different signaling pathways p38 and mitogen-activated protein kinase (MAPK), as well as t